Juvenile Ideopaphic Arthritis

Updated: July 16, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

etodolac

20 to 30 kg: 400 mg orally extended release once a day
31 to 45 kg: 600 mg orally extended release once a day
46 to 60 kg: 800 mg orally extended release once a day
>60 kg: 1000 mg orally extended release once a day

adalimumab-aacf

Humira,cyltezo,hulio or amjevita:

<2 years or <10 kg:
Safety and efficacy not established
>2 years:
<15 kg: Dosage forms not available
15 to <30kg:20mg subcutaneous every two weeks
>30kg:40mg subcutaneous every two weeks

adalimumab-aacf

Abrilada, Hadlima:

<2 years or <10 kg:
Safety and efficacy not established
>2 years:
10 to <15 kgs:10mg subcutaneous every two weeks
15 to >30kgs: 20mg subcutaneous every two weeks
>30kgs: 40mg subcutaneous every two weeks

gold sodium thiomalate (Discontinued)

(Off-label)
1st week- 10 mg intramuscularly
Later 1mg/kg intramuscularly every week
Do not exceed more than 50 mg/dose

Future Trends